The vascular endothelial growth factor (VEGF) decoy receptor soluble VEGF-R1 (sVEGF-R1) is thought to protect the cells that produce it from adverse VEGF signaling. To accomplish this role, a mechanism for pericellular retention of sVEGF-R1 is required. Local retention may also prevent the accumulation of high circulating levels of sVEGF-R1 and resulting interference with homeostatic VEGF functions in remote organs.
S
oluble VEGF receptor 1 (sVEGF-R1) is a naturallyproduced decoy receptor capable of binding and sequestering VEGF-A, VEGF-B and Placental Growth Factor. 1 The primary mRNA is transcribed from a single VEGF-R1 locus and is alternatively spliced to generate either the membranespanning receptor or sVEGF-R1 in a mutually exclusive manner. 2 The fact that sVEGF-R1 is a secreted protein qualifies it as a "trap" capable of titrating extracellular VEGF. Indeed, sVEGF-R1 has been extensively used experimentally for VEGF inhibition. Yet, little is known regarding its natural roles. A notable example of the physiological role of sVEGF-R1 is in the cornea where it is indispensable for maintaining corneal avascularity by virtue of neutralizing VEGF-A. 3 A notable pathophysiological role of sVEGF-R1 is in preeclampsia (PE), the most common and dangerous complication of pregnancy, where excessive levels of sVEGF-R1 secreted by the diseased placenta to the maternal circulation may reach remote organs, primarily the kidney, neutralize podocyte-derived VEGF and cause endotheliosis, hypertension and proteinuria. 4, 5 Although the latter case clearly shows that sVEGF-R1 can access the systemic circulation, the former necessitates its retention within the tissue. Moreover, if sVEGF-R1 is intended to play a protective role against surplus VEGF via its local titration, a mechanism must exist for its pericellular retention in the vicinity of the cells that produce it.
Ig-like domain 4 of VEGF-R1 was previously shown to bind heparin 6 and the fact that this heparin-binding domain is shared with sVEGF-R1 prompted Rajakumar et al to demonstrate that sVEGF-R1 also binds heparin, which can in fact be enriched through binding to a heparin column. 7 Because the human-specific isoform of sVEGF-R1 shares the same heparin-binding domain, we reasoned that it might mediate pericellular retention of both soluble isoforms through bind-ing to cell surface heparan sulfate (HS). HS proteoglycans (HSPGs) are either anchored to the cell surface or present in the ECM and control many biological processes by virtue of binding a host of growth factors, including VEGF. 8 Here, we show that both full-length isoforms of sVEGF-R1 are not only capable of binding to heparin but are also bound to HS in vivo.
We further reasoned that to exert dynamic regulation, binding of sVEGF-R1 to HS is not rigid but rather flexible and actively subjected to regulation. An attractive candidate for such regulation is heparanase, an endo-␤-D-glucuronidase known to be implicated in diverse processes such as angiogenesis, metastasis and inflammation. It has been shown that heparanase-mediated release of HS-bound growth factors plays a major role in the above processes. 9 Here, we extended this biological principle to the HS-bound decoy receptor sVEGF-R1 by showing that heparanase indeed plays a natural role in liberating sVEGF-R1 from its placental reservoir.
Methods

Recombinant Expression of sVEGF-R1 Isoforms
cDNAs encompassing the entire coding region of both soluble receptor isoforms (GenBank sequences EU368830.1 and U01134.1) were subcloned into Bluescript expression vectors and transfected onto T7 polymerase-expressing Hela cells. Twenty-four hours later, media containing the secreted proteins were collected. Protein concentration was determined with sVEGF-R1 ELISA.
Displacement From Heparin Sepharose Columns
Heparin sepharose (GE Healthcare, CL-6B) was packed on chromatography columns according to manufacturer instructions. A 1-g sample of each sVEGF-R1 isoform was loaded and bound to the columns. Proteins were displaced from the columns using increasing NaCl concentrations. Fractions were collected and evaluated for sVEGF-R1 amount by Western blotting as described below.
sVEGF-R1, Heparanase, and Cathepsin L Western Blotting
Human recombinant proteins that were displaced from heparin sepharose columns were run on a separating gel and blotted with the ab9540 antibody (Abcam). Mouse endogenous sVEGF-R1 was immuno-precipitated using the V4262 antibody (Sigma), and immuno blotted using the sc-9029 antibody (Santa-Cruz biotechnology). C2970 antibody (Sigma) was used for human cathepsin L blotting. Human heparanase was detected using the monoclonal antibody 01385-126 (kindly provided by ImClone Systems Inc., New York, NY), recognizing both the 50-kDa subunit and the 65-kDa proheparanase. 10 
sVEGF-R1 In Situ Hybridization
For in situ detection of mouse sVEGF-R1 RNA, paraffin-embedded sections of mouse heart were hybridized with 35 S-labeled riboprobe complementing the first 600 nucleotides of intron 13 of VEGF-R1, as previously described. 11
sVEGF-R1 and Active Heparanase Immunohistochemistry
Paraffin-embedded sections of mouse heart, or human term placenta were used. Antigen retrieval was performed by microwave heating in pH 6 citrate buffer. The 36-1100 antibody (Zymed) was used at a 1:100 dilution to detect sFlt1. The 733 antibody was used at a 1:100 dilution to detect the active form of heparanase. 12 
Heparin Displacement of sVEGF-R1 From Aortic Arches
Mouse aortic arches were isolated, cleaned from adventitia, cut into cylinder segments, and incubated for 24 hours with or without 10 U/mL heparin (Sigma, H0777). Medium was collected and evaluated for sVEGF-R1 levels with sVEGF-R1 ELISA.
Term Human Placental Explants Culture
Term human placentas were excised to small sections, and incubated according to guidelines detailed elsewhere. 13 In short, 75 mg of placental villi were placed in each well, and incubated in DMEM/ F12 medium supplemented with 10% FCS, in 8% oxygen. Incubation time varied according to the different protocols used in each experimental setting.
Heparin Displacement of sVEGF-R1 From Human Placental Villi Explants
Human term placental villi were explanted for 24 hours with different heparin concentrations. sVEGF-R1 levels were determined in media and explanted placental villi using ELISA. Protein concentration of each villi sample was determined using the Bradford assay. Similar protein amount of each villi sample was used to determine sVEGF-R1 concentration.
Heparanase-Overexpressing Transgenic Mice
The generation and characterization of these mice are described elsewhere. 14 
Real-Time PCR
RNA and cDNA were generated from embryonic day (E)16.5 placentas of Wt and heparanase Tg mice. sVEGF-R1 levels were evaluated using SYBR green real time PCR, and normalized according to ␤-actin levels.
The primers used were as follows: sVEGF-R1 forward primer: GGCCCAGAGGAAACGCTCCTC; sVEGF-R1 reverse primer: AATCCAAACACACACCGGGCG; ␤-actin forward primer: AC-CCGCGAGCACAGCTTCTT; ␤-actin reverse primer: GAACTGGTGGCGGGTGTGGA.
Heparanase Inhibition in Human Placental Villi Explants
Heparanase processing and thereby enzymatic activity was indirectly inhibited via a 72-hour incubation with 8 mol/L of the specific 10 Heparanase was directly inhibited via a 48-hour incubation with the neutralizing antibody 733 added to the medium at concentration of 10 g/mL. 12 Heparanse inhibition required a longer incubation time than the 24 hours used for the heparin displacement experiment to elicit an inhibition effect: Heparanase neutralization was evaluated after 48 hours, whereas cathepsin L inhibitor required 72 hours of incubation, as active heparanase can be found in the villi, and longer incubation time allows diminishing its effect.
Enzyme-Linked Immunosorbent Assay
Human sVEGF-R1 levels were determined using the DVR100b sVEGF-R1 ELISA kit (R&D Systems). Mouse sVEGF-R1 levels were determined using the MVR100 sVEGF-R1 ELISA kit (R&D Systems).
Serum and Placentas From Pregnant Women
Serum samples and term placentas were taken with Institutional Review Board approval with the informed consent of pregnant women.
Statistics
Data were analyzed by 2-sample t test. Standard error of the mean (SEM) was calculated as sample standard deviation divided by the square root of the sample size.
Results
sVEGF-R1 Is a Heparin-Binding Protein
To examine the proposition that sVEGF-R1 might be retained in the vicinity of the producing cell through binding to HS, we first examined its ability to bind heparin. Because 2 distinct splice variants of sVEGF-R1 are known to exist, namely the "generic" soluble receptor (sFlt1) and the recently identified human-specific variant (sFlt1-14), 15 we wished to determine whether the previously reported heparin-binding capability of the generic isoform also applies to sFlt1-14. To this end, the respective recombinant proteins were produced in a cell culture, loaded on heparin sepharose columns and subsequently displaced by increasing concentration of NaCl. High concentrations (Ͼ1.1 mol/L) were required to displace the bulk of either protein, demonstrating a capacity to bind heparin at a high affinity ( Figure 1 ). For comparison, 0.8 mol/L NaCl is sufficient to displace VEGF, which is considered a classical heparin-binding growth factor. 16 This experiment also showed that the human-specific soluble receptor, the predominant isoform in the human placenta, binds heparin as efficiently as the canonical isoform. In experiments described herein, the term sVEGF-R1 was interchangeably used for both isoforms on the premise that they have comparable heparin-binding capabilities.
Natural Stores of sVEGF-R1 in the Vessel Wall Are Displaceable by Heparin
To determine whether natural tissue stores of sVEGF-R1 exist, we first searched for sVEGF-R1 reservoir in the vessel wall. Previously, we showed that cultured VSMCs obtained from resected human vessels indeed secrete sVEGF-R1. 15 Here, we examined sections of different mouse organs for sVEGF-R1 production using in situ hybridization with a sVEGF-R1-specific riboprobe. sVEGF-R1 was abundantly expressed in ␣SMA-positive VSMCs of various organs, as can be seen for VSMCs belonging to the outflow tract of the heart (Figure 2A , left). Immuno-staining specific for sVEGF-R1 validated its expression at the protein level in VSMCs of different vessels (Figure 2A, right) . Western blot analysis further showed that high levels of sVEGF-R1 protein are indeed present in the aortic segment examined. Remarkably, the protein detected in the vessel wall was predominantly the decoy soluble receptor and not the membranespanning signaling receptor ( Figure 2B ). To determine whether this sVEGF-R1 store is displaceable by heparin, the aortic segment was excised and incubated ex vivo for 24 hours in the presence or absence of heparin. sVEGF-R1 ELISA was used to determine the amount of sVEGF-R1 released to the conditioned medium. As shown in Figure 2C , heparin treatment resulted in a 6-fold increase in the amount of sVEGF-R1 secreted to the culture medium.
Natural Stores of sVEGF-R1 in the Human Placenta Are Displaceable by Heparin
Reasoning that there are additional physiological arenas where sVEGF-R1 is retained in the tissue, we turned to the human placenta. It is known that the human placenta is a rich source of sVEGF-R1 secreted to the circulation during normal pregnancy, which is even greatly increased in PE. 4, 5 Yet, the notion that the placenta is also a HS-bound depot of sVEGF-R1 has not been considered.
To test this, human placental villi explants were incubated for 24 hours with increasing concentrations of heparin and the amounts of sVEGF-R1 released to the medium ( Figure 3A) or remaining in the tissue ( Figure 3B) were determined. As shown, heparin treatment led to release of sVEGF-R1 to the medium in a dose-dependent manner and was mirror-imaged by a parallel decrease in the protein remaining in the villi. The apparent increase in the amount of sVEGF-R1 released to the medium was not merely a reflection of increased sVEGF-R1 production, as the total amount of sVEGF-R1 was not increased in heparin-treated explants and the only difference was in its relative distribution between the tissue and medium Figure 1 . sVEGF-R1 binding to heparin. Recombinant sFlt1-14 or sFlt1 were loaded on heparin-sepharose column and subsequently displaced by increasing NaCl concentrations. Relative amounts of displaced sFlt1-14 and sFlt1 were determined by Western blotting using an antibody (ab9540) recognizing a shared epitope.
(Online Figure I , available in the Online Data Supplement at http://circres.ahajournals.org).
To extend this finding to an in vivo setting, we resorted to analysis of serum samples obtained from pregnant women treated with the low molecular weight heparin (LMWH) clexane, which is routinely used for prophylaxis of coagulation abnormalities during pregnancy. As shown in Figure 3C , clexane increased the level of sVEGF-R1 released to the circulation by 4-fold. Together, these results established that the level of sVEGF-R1 detectable in the circulation represent only a small fraction of the total amount of bodily sVEGF-R1, the majority of which is stored in tissue reservoirs.
Heparanase Is a Potential Regulator of sVEGF-R1 Release
The presence of sVEGF-R1 tissue stores, on one hand, and its presence in the circulation, on the other hand, argues for an active mechanism governing the retention versus release of this natural VEGF inhibitor. Reasoning that heparanase might play such a regulatory role by virtue of releasing HS-bound sVEGF-R1, we first determined whether heparanase is indeed produced in the relevant tissue environment. To this end, we analyzed term human placentas for heparanase production, as the placenta is known to be the major source of circulating sVEGF-R1 in pregnancy. Western blot analysis revealed that both the precursor inactive protein, as well as the proteolytically processed active enzyme, are readily detected in the placenta ( Figure  4A ). Correspondingly, cathepsin L, the protease responsible for processing of the 65 kDa precursor protein, 10 was also detectable in the placenta ( Figure 4A ).
To determine localization of active heparanase within the placenta, in situ immuno-histochemical analysis with an antibody that recognizes primarily active heparanase was performed. As shown in Figure 4B , heparanase was predominantly detected in syncytiotrophoblasts and in placental syncytial knots. Remarkably, these locales completely coincide with the sites of sVEGF-R1 production, 15 consistent with the proposition that heparanase may function in sVEGF-R1 release.
Transgenic Heparanase Overexpression Increases the Level of Circulating sVEGF-R1
To examine whether heparanase is capable of releasing sVEGF-R1 into the systemic circulation, transgenic mice in which heparanase expression is controlled by a ubiquitous promoter driving its overexpression in all tissues 14 was used. Higher levels of sVEGF-R1 were detected in the serum of heparanase-overexpressing mice in comparison to littermate controls (230 pg/mL and 140 pg/mL, respectively) ( Figure  5A ). This significant 65% increase likely reflects sVEGF-R1 release from different tissue depots.
A similar analysis was also performed in pregnant mice where circulating sVEGF-R1 can reach levels Ͼ180-fold higher than in nonpregnant mice. Control mice showed a gestational stage-dependent increase in circulating sVEGF-R1 reaching 25 ng/mL on average at E16.5. Remarkably, heparanase overexpression resulted in a significant increase in the levels of circulating sVEGF-R1 at all stages and was 3.5-fold higher by E16.5 ( Figure 5B ). This result could not be explained by a difference in embryo number, which was comparable to controls (data not shown). Noteworthy, at this time point, the level of placental sVEGF-R1 expression was indistinguishable between control and heparanase-overexpressing transgenic mice, indicating that heparanase indeed act to release sVEGF-R1 from its placental stores (Online Figure II) .
These results corroborate the notion that only a minor fraction of placentally produced sVEGF-R1 is reaching the circulation and further suggest that heparanase might play a role in sVEGF-R1 release.
Heparanase Inhibition Decreases sVEGF-R1 Release From the Placenta
To determine whether heparanase plays a natural role in regulated release of placental sVEGF-R1, we used 2 independent approaches for inhibiting endogenous heparanase: pre- . Note that cathepsin L, the protease mediating heparanase activation, is also expressed in the placenta. B, In situ immunohistochemistry of human term placenta section with an antibody detecting primarily the active form of heparanase (ab733). Note extensive staining in syncytiotrophoblasts, as well as in syncytial knots, the degenerative structures previously shown to be the major source of placental sFlt1-14 production. Figure 5 . Increased circulating levels of sVEGF-R1 in heparanase-overexpressing mice. A, Circulating levels of sVEGF-R1 were determined by ELISA in female transgenic mice overexpressing heparanase (Tg) and in wild-type controls (Wt). Transgenic: nϭ4; wild type: nϭ3; *PϽ0.02. B, A similar analysis was performed during pregnancy. Blood was withdrawn and serum was analyzed at 3 time points (E11.5, E13.5, and E16.5). Each black line represents sVEGF-R1 levels of a wild-type pregnant mouse, and each red line represents sVEGF-R1 levels of a heparanase transgenic mouse (nϭ6 for each group). An increase in sVEGF-R1 levels can be seen in normal wild-type pregnancies as pregnancy develops. At all time points examined, sVEGF-R1 levels of the heparanase-overexpressing mice exceeded the respective normal levels by a factor of 3 to 4.
venting processing and activation of the proenzyme via cathepsin L inhibition and direct inhibition of heparanase through the use of a neutralizing antibody. Inhibition of cathepsin L activity in human placental villi explants resulted in a 35% reduction in sVEGF-R1 secreted to the medium ( Figure 6A ). Likewise, heparanase neutralizing antibody reduced the level of sVEGF-R1 secreted to the culture medium by 32% ( Figure 6B ). This was associated with a parallel similar increase in sVEGF-R1 retained in the villi (data not shown). These results indicate that heparanase is a natural regulator of sVEGF-R1 release from the placenta.
Discussion
Here, we showed that the majority of sVEGF-R1 is retained in the vicinity of the producing cell in spite of it being a secreted protein. Further, we showed that pericellular retention of this natural VEGF decoy receptor is mediated through its high affinity binding to HS and that its release is controlled at least in part by heparanase.
Existence of tissue depots of sVEGF-R1 provide a basis for the notion that the primary physiological role of sVEGF-R1 is to sequester VEGF locally thereby granting the producing cell protection against unwarranted VEGF signaling. Thus, it can be argued that the abundant presence of sVEGF-R1 in the vessel wall shown here has a functional role in protecting VSMCs from adverse VEGF signaling. Consistent with this proposition is our previous observation that the mRNA transcribed from the VEGF-R1 locus in VSMCs is spliced in a mode yielding exclusively sVEGF-R1 15 (but not the signaling transmembrane receptor) and results shown here that only sVEGF-R1 protein is produced and deposited in the VSMC layer ( Figure 2 ). Because VEGF is known to cause vasodilatation, 17, 18 it could be speculated that its local titration keeps VEGF-induced vasodilatation in check.
Local retention of sVEGF-R1, thereby preventing its systemic release, might also be required to avoid indiscriminate neutralization of VEGF in remote organs. This may include interference with homeostatic function of VEGF in the kidney and in additional organs where constitutive VEGF signaling is needed to maintain endothelial fenestrations. Indeed, it was shown that excessive systemic release of placentally-produced sVEGF-R1 may cause PE through interfering with normal VEGF kidney function. 4, 5 It may be generalized that high levels of circulating sVEGF-R1 detectable in pathological settings likely reflect a failure to retain it locally (see below). It is important to keep in mind that in the human, 2 isoforms of the decoy receptor coexist, namely the generic sFlt1 and the human-specific sFlt1-14, with the latter predominating in normal and PE pregnancies. 15 Local retention of sVEGF-R1 is mediated by cell-bound or ECM deposited HS. This was shown in 2 independent ways: First, by showing sVEGF-R1 displacement and release by heparin and LMWH and second, by demonstrating increased levels of sVEGF-R1 in the circulation of transgenic mice overexpressing heparanase. These experiments allow for the evaluation of the relative amounts of retained versus released sVEGF-R1 in respective tissues. For example, the finding that the amount of sVEGF-R1 displaceable from the vessel wall of the aortic arch by heparin largely exceeds the normally secreted amount by 6-fold ( Figure 2C) indicates that the majority of the decoy receptor is stored rather than released. Interestingly, levels of sVEGF-R1 detectable in the vessel wall were found to vary depending on the anatomic location of the respective arterial segment (data not shown). Likewise, the finding that heparanase overexpression in pregnant mice results in 3 to 4-fold increase of circulating sVEGF-R1 indicates that only a minor fraction of sVEGF-R1 produced by the placenta, apparently the richest storage depot of sVEGF-R1, finds its way to the circulation. Because circulating sVEGF-R1 has been causally implicated in the development of PE, 5 existence of a large placental reservoir of this potentially harmful agent may greatly impact the pathogenic process. In this regard, mechanisms accounting for balancing retained versus secreted sVEGF-R1 are of great importance.
It is likely that increased levels of circulating sVEGF-R1 in PE reflects a limited retention capacity by placental HS which is overwhelmed by excessive production of sVEGF-R1. Several parameters may determine the retention capacity of secreted sVEGF-R1. First is the repertoire of placental HSPGs and their levels, which may vary. For example, placental expression of the key HSPG syndecan 1 was shown Figure 6 . Heparanase loss-of-function reduces sVEGF-R1 release in human placental villi explants. Villi from human term placenta were cultured as described in Methods. A, Specific cathepsin L inhibitor (concentration, 8 mol/L) (Calbiochem, catalog no. 219427) was added to the culture medium and sVEGF-R1 was determined 3 days later. *PϽ0.03; nϭ4. B, Heparanse neutralizing antibody (ab733) was added to the culture medium and sVEGF-R1 was determined 2 days later. *PϽ0.02; nϭ6.
to diminish in preeclampsia 19 and thereby possibly reduce overall retention capacity. Second, heparanase activity responsible for release of HSPG-bound proteins in general, might also participate in sVEFGF-R1 release. Indeed, heparanase is expressed in the same locales shown previously to produce sVEGF-R1, and has a natural role in regulating sVEGF-R1 release, as demonstrated in loss-of-function experiments described above ( Figure 6 ). The observed 32% to 35% decrease in sVEGF-R1 secretion is likely an underestimation considering that the 2 reagents used, ie, heparanase neutralizing antibody and a cathepsin-L inhibitor, do not fully block heparanase activity (not shown). The fraction of sVEGF-R1 released by heparanase in the normal and PE placenta is yet to be determined. Heparanse is constitutively expressed in the placenta in small fetal vessels and in a variety of trophoblast subpopulations with different potentials for invasion. Interestingly, heparanase expression was shown to be progressively up regulated during pregnancy, 20 which grossly correlates with the progressive accumulation of sVEGF-R1 in the circulation. 4 Yet, a comparison of heparanase levels between normal and PE placenta did not reveal additional increase in PE (data not shown). Regardless of the mechanisms accounting for sVEGF-R1 retention, the fact that only circulating sVEGF-R1 is pathogenic, suggests that inhibition of its systemic release (eg, via inhibition of heparanase activity) could be harnessed therapeutically.
Neutralization of VEGF function in the kidney glomerular basement membrane (GBM) is known to be the primary cause of PE-associated renal damage. 5, 21 Specifically, it has been shown that podocyte-derived VEGF acts on VEGF receptors displayed on nearby endothelial cells. 21 Thus, sVEGF-R1 entrapped in the HS-rich GBM is bound to interfere with this homeostatic VEGF function. Accordingly, inhibition of sVEGF-R1 binding to HS (eg, with LMWH) in the target organ may also be beneficial. Consistent with this proposition, is a recent report showing that the low molecular weight heparin dalteparin is effective in decreasing the recurrence of placental-mediated complications in women without thrombophilia. 22 Noteworthy, HSPG-bound proteins released by heparanase are still bound to a sugar moiety of an average size of 10 to 20 sugar units, which may alter its biological activity. 9 Thus, sVEGF-R1 released by heparanase may also have different affinity for GBM binding than sVEGF-R1 released by another mode.
In conclusion, this study uncovered a previously unrecognized level of VEGF regulation, namely, bioavailability of its decoy receptor determined by its local storage versus its systemic release. The first situation, we argue, is intended for keeping in check local VEGF action, whereas the second situation is largely associated with pathological VEGF neutralization. Further mechanistic insights on factors governing retention versus release of sVEGF-R1 might be harnessed for ameliorating the pathological consequences of excessive circulating sVEGF-R1 acting on remote organs.
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